Clinical Research Directory
Browse clinical research sites, groups, and studies.
Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes
Sponsor: Seoul National University Bundang Hospital
Summary
This exploratory pilot study aims to evaluate the cognitive improvement effects of combination therapy with cilostazol (200 mg) and ginkgo biloba extract (160 mg) in elderly patients with type 2 diabetes mellitus. Both agents have demonstrated potential cognitive benefits through mechanisms such as enhanced cerebral blood flow, anti-inflammatory activity, and neuroprotection. Given the increased risk of cognitive decline and dementia in patients with type 2 diabetes, and the need for preventive strategies, this study will investigate whether the combination therapy can prevent or mitigate cognitive deterioration. Findings from this study may provide foundational data for the future development of therapeutic interventions targeting cognitive impairment in patients with diabetes.
Official title: Impact of Cilostazol and Ginkgo Leaf Extract on Cognitive Function in Elderly Patients With Type 2 Diabetes
Key Details
Gender
All
Age Range
60 Years - Any
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2025-01-01
Completion Date
2027-06-30
Last Updated
2025-05-25
Healthy Volunteers
No
Interventions
Cilostazol / Ginko Leaf Dried Ext.
Patients will receive a light green, oval-shaped, sustained-release film-coated tablet containing a combination of cilostazol (200 mg) and ginkgo biloba extract (160 mg), administered orally once daily.
Placebo
Patients will receive a placebo identical in taste, aroma, and formulation to the active treatment, administered orally once daily.
Locations (1)
Seoul National University Bundang Hospital
Seongnam-si, South Korea